ARNI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Mar 2024 @ 12:17):

Stats
Today's Volume	350.00
Average Volume	5.00
Market Cap	171 736
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2016-08-15	Belldegrun Arie	Buy	714 285	Common Stock
2016-08-15	Belldegrun Arie	Buy	357 142	2016 Series F Warrants (right to buy)

INSIDER POWER
0.00
Last 89 transactions
Buy: 17 291 951 \| Sell: 681 614

Volume Correlation

Long: -0.53 (weak negative)

Short: -0.61 (weak negative)

Signal:(0.671) Neutral

Arno Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arno Therapeutics, Inc. Correlation - Currency/Commodity

0.00
( neutral )

Arno Therapeutics, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q3	2016
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0900

Q2	2016
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0500

Q1	2016
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.100

Financial Reports:

No articles found.

Arno Therapeutics, Inc.

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.